KromaTiD, Inc.

KromaTiD is a biotechnology company specializing in high-resolution, single-cell genomic structural analysis. The company provides proprietary platforms, including dGH (directional Genomic Hybridization), to detect chromosomal structural rearrangements, inversions, and translocations, which are critical for quality control and safety assessment in cell and gene therapy development. KromaTiD serves as a partner to pharmaceutical, biotechnology, and academic research organizations, supporting them from early-stage discovery through IND-enabling studies and clinical batch release. Their technology is designed to provide the high-confidence, actionable data required by regulators to ensure the genomic integrity of advanced therapeutic products.